Article: BioAdvance Funds TREVENTIS to Advance Alzheimer's Drug Discovery.

PHILADELPHIA -- BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, announced today a $550,000 seed-stage investment in TREVENTIS Corporation, an emerging life sciences company in Southeastern Pennsylvania.

TREVENTIS is focused on developing disease-modifying small molecule drugs and diagnostics for early stage treatment of Alzheimer's disease (AD) and other major neurodegenerative disorders. The Company's proprietary discovery technology targets protein misfolding to inhibit the aggregation of amyloid proteins, including beta-amyloid (plaque) and tau proteins (tangles), both associated with the neuronal loss in Alzheimer's disease. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!